Home > Journals > The Journal of Cardiovascular Surgery > Past Issues > The Journal of Cardiovascular Surgery 2002 October;43(5) > The Journal of Cardiovascular Surgery 2002 October;43(5):729-34

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

THE JOURNAL OF CARDIOVASCULAR SURGERY

A Journal on Cardiac, Vascular and Thoracic Surgery


Indexed/Abstracted in: BIOSIS Previews, Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 2,179


eTOC

 

ORIGINAL ARTICLES  THORACIC SECTION


The Journal of Cardiovascular Surgery 2002 October;43(5):729-34

Copyright © 2009 EDIZIONI MINERVA MEDICA

language: English

Clinical significance of the preoperative serum-soluble intercellular adhesion molecule-1 in non-small cell lung cancer

Kamiyoshihara M. 1, Kawashima O. 2, Otani Y. 3, Morishita Y. 3

1 Department of Thoracic and Cardiovascular Surgery Maebashi Red Cross Hospital, Maebashi, Gunma, Japan 2 Department of Surgery National Sanatorium Nishigunma Hospital, Shibukawa, Gunma, Japan 3 Second Department of Surgery Gunma University School of Medicine, Maebashi, Gunma, Japan


PDF  


Background. The ser­um-sol­u­ble inter­cel­lu­lar adhe­sion mole­cule-1 (sICAM-1) is report­ed to cor­re­late ­with ­both the met­a­stat­ic poten­tial and a ­poor prog­no­sis. We ana­lyzed the sICAM-1 con­cen­tra­tions and inves­ti­gat­ed wheth­er or not the ser­um lev­els of ­these adhe­sion mole­cules in the periph­er­al ­venous ­blood ­could ­help pre­dict the clin­i­cal stag­ing in ­patients ­with ­NSCLC.
Methods. From January to December 1999, 66 ­patients (79.5%) under­went ­either a lobec­to­my or a pneu­mo­nec­to­my ­with a med­i­as­ti­nal ­lymph ­node dis­sec­tion at the National Sanatorium Nishi-Gunma Hospital.
Results. The sICAM-1 con­cen­tra­tion in the ­NSCLC ­patients was a ­mean val­ue of 212.0±106.6 ng/ml. In con­trast, the con­cen­tra­tion of sICAM-1 in 20 ­healthy con­trols was a ­mean val­ue of 117.9±64.1 ng/ml. In ­patients ­with ­NSCLC, the sICAM-1 con­cen­tra­tions ­were sig­nif­i­cant­ly high­er ­than in the nor­mal con­trol ­group (p=0.002). In addi­tion, the dif­fer­ence in the ser­um con­cen­tra­tions was sig­nif­i­cant ­between the ­patients ­with T1 and T2 dis­ease (p=0.042), and N0 and N2 ­patients (p=0.042). No sig­nif­i­cant dif­fer­enc­es ­were ­observed in ­aging, smok­ing his­to­ry, his­to­log­i­cal ­type, or path­o­log­i­cal stag­ing.
Conclusions. The sICAM-1 con­cen­tra­tions in ­lung can­cer ­patients are ­thus sug­gest­ed to ­play a ­role in stag­ing, and may ­also ­serve as a use­ful indi­ca­tor of ­advanced dis­ease.

top of page

Publication History

Cite this article as

Corresponding author e-mail